BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28583043)

  • 1. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
    Ozaki T; Nakamura H; Izutsu N; Masaie H; Ishikawa J; Kinoshita M
    Interv Neuroradiol; 2017 Oct; 23(5):527-530. PubMed ID: 28583043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia].
    Nakaya A; Ebitani M; Monzen T; Nagno T; Saito F; Yaoita Y
    Rinsho Shinkeigaku; 2019 Jul; 59(7):418-424. PubMed ID: 31243247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature.
    Kassem N; Ismail OM; Elomri H; Yassin MA
    Am J Case Rep; 2017 Jul; 18():794-798. PubMed ID: 28706179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.
    Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
    Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
    J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
    Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
    Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
    Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
    Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
    Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
    Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
    IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
    Yamauchi T; Ueda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
    Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
    Cancer Treat Rev; 2012 May; 38(3):241-8. PubMed ID: 21840128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia].
    Pan LQ; Liu WX; Zhu Y; Hong M; Qiao S; Li JY; Qian SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1545-9. PubMed ID: 25543472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Jarkowski A; Sweeney RP
    Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.